{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:47:29Z","timestamp":1787024849686,"version":"build-2736575974"},"reference-count":44,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100003407","name":"Italian Ministry for Education and Science","doi-asserted-by":"publisher","award":["2017XYBP2R"],"award-info":[{"award-number":["2017XYBP2R"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003056","name":"Ente Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","award":["CRF2020.1395"],"award-info":[{"award-number":["CRF2020.1395"]}],"id":[{"id":"10.13039\/501100003056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The positively charged membrane impermeant sulfonamides were evaluated as a remarkable\nclass of carbonic anhydrase inhibitors (CAIs) previously. Without affecting the human carbonic anhydrase (hCA),\ncytosolic isoforms hCA I and II, inhibition of two membrane-associated isoforms hCA IX and XII especially overexpressed\nin hypoxic tumour cells, makes the pyridinium salt derivatives potent promising therapeutic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>A novel series of tri, tetra, and cyclo-substituted pyridinium salt derivatives of the lead compound 2-\n(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide has been prepared by using sixteen different pyrylium salts,\nfor the search of selective inhibitors of transmembrane tumour-associated human carbonic anhydrase hCA IX and XII.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Molecular modeling studies were carried out to understand and rationalize the in vitro enzyme inhibition\ndata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Six of the new compounds showed good inhibitory profiles with low nanomolar range (&lt; 100 nM) against\nhCA IX\/XII, and compound 5 showed excellent potency with Ki values lower than 10 nM. In addition, molecular modelling\nstudies have presented the possible binding modes of the ligands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Most of the compounds displayed potent inhibitory activity against the tumor-associated hCA IX and XII\nin the low nanomolar range and selectivity over the off-targeted isoforms hCA I and II. Due to their cationic structure\nand membrane-impermeant behavior, it is also expected to maximize the selectivity over cytosolic isoforms hCA I\/II\nwhile inhibiting tumor overexpressed isoforms hCA XI\/XII of new compounds in in vivo conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871520622666220207092123","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:27:17Z","timestamp":1644373637000},"page":"2637-2646","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Pyridinium Salt Derivatives of 2-(Hydrazinocarbonyl)-3-phenyl-1H-indole-5-\nsulfonamide as Selective Inhibitors of Tumour-Related Human Carbonic Anhydrase\nIsoforms IX and XII"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-1945","authenticated-orcid":true,"given":"\u00d6zlen","family":"G\u00fczel-Akdemir","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-4733","authenticated-orcid":true,"given":"K\u00fcbra","family":"Demir-Yaz\u0131c\u0131","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-1900","authenticated-orcid":true,"given":"Daniela","family":"Vullo","sequence":"additional","affiliation":[{"name":"Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Universit\u00e0 degli Studi di Firenze, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":true,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[{"name":"Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Universit\u00e0 degli Studi di Firenze, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-0471","authenticated-orcid":true,"given":"Atilla","family":"Akdemir","sequence":"additional","affiliation":[{"name":"Computer-aided Drug Discovery Laboratory, Department of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"Siegel R.L.","year":"2020","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2020. CA Cancer J Clin 2020,70(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=2","unstructured":"World Health Organization. Cancer Homepage. Available from: Accessed February 28, 2021) https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1"},{"key":"ref=3","unstructured":"World Health Organization. Cancer Homepage. Available from: (Accessed February 28, 2021). https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/cancer"},{"key":"ref=4","unstructured":"World Health Organization. Cancer Homepage. Available from: (Accessed February 28, 2021) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"Dawson M.A.","year":"2012","unstructured":"Dawson M.A.; Kouzarides T.; Cancer epigenetics: from mechanism to therapy. Cell 2012,150(1),12-27","journal-title":"Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"Brahimi-Horn M.C.","year":"2007","unstructured":"Brahimi-Horn M.C.; Chiche J.; Pouyss\u00e9gur J.; Hypoxia and cancer. J Mol Med (Berl) 2007,85(12),1301-1307","journal-title":"J Mol Med (Berl)"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"Petrova V.","year":"2018","unstructured":"Petrova V.; Annicchiarico-Petruzzelli M.; Melino G.; Amelio I.; The hypoxic tumour microenvironment. Oncogenesis 2018,7(1),10","journal-title":"Oncogenesis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"Tr\u00e9dan O.","year":"2007","unstructured":"Tr\u00e9dan O.; Galmarini C.M.; Patel K.; Tannock I.F.; Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007,99(19),1441-1454","journal-title":"J Natl Cancer Inst"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0968-0004(98)01344-9","volume":"24","author":"Dang C.V.","year":"1999","unstructured":"Dang C.V.; Semenza G.L.; Oncogenic alterations of metabolism. Trends Biochem Sci 1999,24(2),68-72","journal-title":"Trends Biochem Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"Vander Heiden M.G.","year":"2009","unstructured":"Vander Heiden M.G.; Cantley L.C.; Thompson C.B.; Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009,324(5930),1029-1033","journal-title":"Science"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"Wilson W.R.","year":"2011","unstructured":"Wilson W.R.; Hay M.P.; Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011,11(6),393-410","journal-title":"Nat Rev Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1677\/erc.1.01290","volume":"13","author":"Patiar S.","year":"2006","unstructured":"Patiar S.; Harris A.L.; Role of hypoxia-inducible factor-1\u03b1 as a cancer therapy target. Endocr Relat Cancer 2006,13(Suppl. 1),S61-S75","journal-title":"Endocr Relat Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","volume":"27","author":"Supuran C.T.","year":"2018","unstructured":"Supuran C.T.; Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018,27(12),963-970","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","volume":"7","author":"Supuran C.T.","year":"2017","unstructured":"Supuran C.T.; Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017,7(3),48","journal-title":"Metabolites"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/metabo10100412","volume":"10","author":"Angeli A.","year":"2020","unstructured":"Angeli A.; Carta F.; Nocentini A.; Winum J.Y.; Zalubovskis R.; Akdemir A.; Onnis V.; Eldehna W.M.; Capasso C.; Simone G.; Monti S.M.; Carradori S.; Donald W.A.; Dedhar S.; Supuran C.T.; Carbonic anhydrase inhibitors targeting metabolism and tumor micro-environment. Metabolites 2020,10(10),412","journal-title":"Metabolites"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"Graham K.","year":"2018","unstructured":"Graham K.; Unger E.; Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine 2018,13,6049-6058","journal-title":"Int J Nanomedicine"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/13543776.2018.1508453","volume":"28","author":"Nocentini A.","year":"2018","unstructured":"Nocentini A.; Supuran C.T.; Carbonic anhydrase inhibitors as antitumor\/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat 2018,28(10),729-740","journal-title":"Expert Opin Ther Pat"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3554","volume":"10","author":"Neri D.","year":"2011","unstructured":"Neri D.; Supuran C.T.; Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011,10(10),767-777","journal-title":"Nat Rev Drug Discov"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","volume":"38","author":"Pastorekova S.","year":"2019","unstructured":"Pastorekova S.; Gillies R.J.; The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019,38(1-2),65-77","journal-title":"Cancer Metastasis Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1568009023334060","volume":"2","author":"Casini A.","year":"2002","unstructured":"Casini A.; Scozzafava A.; Mastrolorenzo A.; Supuran L.T.; Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002,2(1),55-75","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4155\/fmc.14.68","volume":"6","author":"Carta F.","year":"2014","unstructured":"Carta F.; Supuran C.T.; Scozzafava A.; Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem 2014,6(10),1149-1165","journal-title":"Future Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","volume":"31","author":"Supuran C.T.","year":"2016","unstructured":"Supuran C.T.; How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016,31(3),345-360","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=23","author":"Supuran C.T.","year":"2016","unstructured":"Supuran C.T.; De Simone G.;  Carbonic Anhydrases as Biocatalysts 2016","journal-title":"Carbonic Anhydrases as Biocatalysts"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0223-5234(98)80017-2","volume":"33","author":"Supuran C.T.","year":"1998","unstructured":"Supuran C.T.; Scozzafava A.; Ilies M.A.; Iorga B.; Cristea T.; Briganti F.; Chiraleu F.; Banciu M.D.; Carbonic anhydrase inhibitors - part 53. synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: the first non-polymeric membrane-impermeable inhibi-tors with selectivity for isozyme IV. Eur J Med Chem 1998,33(7-8),577-594","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bmcl.2003.12.029","volume":"14","author":"Pastorekova S.","year":"2004","unstructured":"Pastorekova S.; Casini A.; Scozzafava A.; Vullo D.; Pastorek J.; Supuran C.T.; Carbonic anhydrase inhibitors: the first selective, mem-brane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004,14(4),869-873","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"Supuran C.T.","year":"2008","unstructured":"Supuran C.T.; Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008,7(2),168-181","journal-title":"Nat Rev Drug Discov"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1021\/jm031079w","volume":"47","author":"Casey J.R.","year":"2004","unstructured":"Casey J.R.; Morgan P.E.; Vullo D.; Scozzafava A.; Mastrolorenzo A.; Supuran C.T.; Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004,47(9),2337-2347","journal-title":"J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"103104204","DOI":"10.1016\/j.bioorg.2020.104204","author":"Akocak S.","year":"2020","unstructured":"Akocak S.; G\u00fczel-Akdemir \u00d6.; Kishore Kumar Sanku R.; Russom S.S.; Iorga B.I.; Supuran C.T.; Ilies M.A.; Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorg Chem 2020,103104204","journal-title":"Bioorg Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/chin.199046177","volume":"45","author":"Ergen\u00e7 N.","year":"1990","unstructured":"Ergen\u00e7 N.; Salman A.; G\u00fcrsoy A.; Bankaolu, G. Synthesis and antifungal evaluation of some 3-phenyl-2,5-disubstituted indoles de-rived from new ethyl-2-benzyl-2-[N-(aryl)hydrazono] ethanoates. Pharmazie 1990,45(5),346-347","journal-title":"Pharmazie"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bmcl.2007.10.110","volume":"18","author":"G\u00fczel O.","year":"2008","unstructured":"G\u00fczel O.; Temperini C.; Innocenti A.; Scozzafava A.; Salman A.; Supuran C.T.; Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett 2008,18(1),152-158","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9113","DOI":"10.1016\/j.bmc.2008.09.032","volume":"16","author":"G\u00fczel O.","year":"2008","unstructured":"G\u00fczel O.; Innocenti A.; Scozzafava A.; Salman A.; Parkkila S.; Hilvo M.; Supuran C.T.; Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. Bioorg Med Chem 2008,16(20),9113-9120","journal-title":"Bioorg Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1016\/j.bmcl.2009.04.068","volume":"19","author":"G\u00fczel O.","year":"2009","unstructured":"G\u00fczel O.; Maresca A.; Scozzafava A.; Salman A.; Balaban A.T.; Supuran C.T.; Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. Bioorg Med Chem Lett 2009,19(11),2931-2934","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","volume":"246","author":"Khalifah R.G.","year":"1971","unstructured":"Khalifah R.G.; The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971,246(8),2561-2573","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.bmcl.2004.12.053","volume":"15","author":"Vullo D.","year":"2005","unstructured":"Vullo D.; Innocenti A.; Nishimori I.; Pastorek J.; Scozzafava A.; Pastorekov\u00e1 S.; Supuran C.T.; Carbonic anhydrase inhibitors. Inhibi-tion of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett 2005,15(4),963-969","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/prot.22234","volume":"75","author":"Labute P.","year":"2009","unstructured":"Labute P.; Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins 2009,75(1),187-205","journal-title":"Proteins"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/jcc.20933","volume":"29","author":"Labute P.","year":"2008","unstructured":"Labute P.; The generalized Born\/volume integral implicit solvent model: estimation of the free energy of hydration using London disper-sion instead of atomic surface area. J Comput Chem 2008,29(10),1693-1698","journal-title":"J Comput Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"Phillips J.C.","year":"2005","unstructured":"Phillips J.C.; Braun R.; Wang W.; Gumbart J.; Tajkhorshid E.; Villa E.; Chipot C.; Skeel R.D.; Kal\u00e9 L.; Schulten K.; Scalable molecu-lar dynamics with NAMD. J Comput Chem 2005,26(16),1781-1802","journal-title":"J Comput Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jlac.19113840205","volume":"384","author":"Baeyer A.","year":"1911","unstructured":"Baeyer A.; Piccard J.; Untersuchungen \u00fcber das dimethylpyron. Justus Liebigs Ann Chem 1911,384(2),208-224","journal-title":"Justus Liebigs Ann Chem"},{"key":"ref=39","author":"Balaban A.T.","year":"1982","unstructured":"Balaban A.T.; Dinculescu A.; Dorofeenko G.N.; Fischer G.W.; Koblik A.V.; Mezheritskii V.V.; Schroth W.;  Pyrylium Salts: Syntheses, Reactions and Physical Properties 1982","journal-title":"Pyrylium Salts: Syntheses, Reactions and Physical Properties"},{"key":"ref=40","first-page":"1","volume":"22","author":"Balaban A.T.","year":"1966","unstructured":"Balaban A.T.; Toma C.; Reactions of pyrylium salts with nucleophiles\u2014IV: isolation of an intermediate in the conversion of 2, 4, 6-triphenylpyrylium perchlorate into 2, 4, 6-triphenylpyridine by ammonia. Tetrahedron 1966,22,1-8","journal-title":"Tetrahedron"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1039\/p19820000117","author":"Katritzky A.R.","year":"1982","unstructured":"Katritzky A.R.; Lloyd J.M.; Patel R.C.; The preparation of pyridiniums from pyryliums. J Chem Soc, Perkin Trans 1 1982,117-123","journal-title":"J Chem Soc, Perkin Trans 1"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1016\/j.bmc.2013.06.029","volume":"21","author":"Akdemir A.","year":"2013","unstructured":"Akdemir A.; G\u00fczel-Akdemir O.; Scozzafava A.; Capasso C.; Supuran C.T.; Inhibition of tumor-associated human carbonic anhydrase isozymes IX and XII by a new class of substituted-phenylacetamido aromatic sulfonamides. Bioorg Med Chem 2013,21(17),5228-5232","journal-title":"Bioorg Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/acsami.0c21607","volume":"13","author":"Kudryavtseva V.","year":"2021","unstructured":"Kudryavtseva V.; Boi S.; Read J.; Guillemet R.; Zhang J.; Udalov A.; Shesterikov E.; Tverdokhlebov S.; Pastorino L.; Gould D.J.; Sukhorukov G.B.; Biodegradable defined shaped printed polymer microcapsules for drug delivery. ACS Appl Mater Interfaces 2021,13(2),2371-2381","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcis.2019.01.103","volume":"541","author":"Rutkowski S.","year":"2019","unstructured":"Rutkowski S.; Si T.; Gai M.; Sun M.; Frueh J.; He Q.; Magnetically-guided hydrogel capsule motors produced via ultrasound assisted hydrodynamic electrospray ionization jetting. J Colloid Interface Sci 2019,541,407-417","journal-title":"J Colloid Interface Sci"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220207092123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200866\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871520622666220207092123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T10:46:25Z","timestamp":1691664385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200866\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520622666220207092123","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}